Therapeutic drug monitoring of mood stabilizers in medicaid patients with bipolar disorder

American Journal of Psychiatry

Volumn 156, Issue 7, 1999, Pages 1014-1018

  Marcus, Steven C ^a,b   Olfson, Mark ^a   Pincus, Harold A ^a   Zarin, Deborah A ^a   Kupfer, David J ^a  

^a AMERICAN PSYCHIATRIC ASSOCIATION   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LITHIUM; VALPROIC ACID;

ADULT; ARTICLE; DEMOGRAPHY; DRUG MONITORING; FEMALE; HUMAN; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MANIC DEPRESSIVE PSYCHOSIS; MENTAL HEALTH SERVICE; PRIORITY JOURNAL; THYROID FUNCTION TEST;

ADOLESCENT; ADULT; BIPOLAR DISORDER; BLOOD CHEMICAL ANALYSIS; CARBAMAZEPINE; CASE MANAGEMENT; DRUG MONITORING; FEMALE; HEALTH CARE COSTS; HUMANS; KIDNEY FUNCTION TESTS; LITHIUM; MALE; MANAGED CARE PROGRAMS; MEDICAID; MIDDLE AGED; THYROID FUNCTION TESTS; UNITED STATES; VALPROIC ACID;

EID: 0032971177     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Wyatt RJ, Henter I: An economic evaluation of manic-depressive illness - 1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30:213-219
2. Janicak PG: The relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. J Clin Psychiatry 1993; 54(Sept suppl): 35-41
3. Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, Lavelle J: Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321:1489-1493
4. Maj M, Starace F, Nolfe G, Kemali D: Minimum plasma lithium levels required for effective prophylaxis in DSM III bipolar disorder: a prospective study. Pharmacopsychiatry 1986; 19: 420-423
5. Aronson JK, Hardman M: Why monitor drug therapy? BMJ 1992; 305:947-948
6. Eadie MJ: The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. Clin Pharmacokinet 1995; 29:29-35
7. Ried LD, Horn JR, McKenna DA: Therapeutic drug monitoring reduces toxic drug reactions: a meta-analysis. Ther Drug Monit 1990; 12:72-78
8. Kehoe RF, Mander AJ: Lithium treatment: prescribing and monitoring habits in hospital and general practice. BMJ 1992; 304:552-554
9. Goodwin FK, Jamison KR: Manic Depressive Illness. New York, Oxford University Press, 1990
10. Tomson T: Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Arch Neurol 1984;41:830-834
11. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Bipolar Disorder. Am J Psychiatry 1994; 151(Dec suppl)
12. Frances A, Docherty JP, Kahn DA: The expert consensus guideline series: treatment of bipolar disorder. J Clin Psychiatry 1996; 57(suppl 12A):1-88
13. Bureau of the Census: 1990 Summary Tape File 3B (STF 3B) Technical Documentation. Washington, DC, US Department of Commerce, Bureau of the Census, 1990
14. Bendz H, Aurell M, Balldin J, Mathe AA, Sjodin I: Kidney damage in long-term lithium patients: a cross-sectional study of patients with 15 years or more on lithium. Nephrol Dial Transplant 1994; 9:1250-1254
15. Walker RG: Lithium nephrotoxicity. Kidney Int Suppl 1993; 42: S93-S98
16. Lurie N, Popkin M, Dysken M, Moscovice I, Finch M: Accuracy of diagnoses of schizophrenia in Medicaid claims. Hosp Community Psychiatry 1992; 43:69-71
17. Preskorn SH, Fast GA: Therapeutic drug monitoring for antidepressants: efficacy, safety and cost effectiveness. J Clin Psychiatry 1991; 52:23-33
18. Simmons SA, Perry PJ, Rickert ED, Brown JL: Cost benefit of prospective pharmacokinetic dosing of nortriptyline in depressed inpatients. J Affect Disord 1985; 8:47-53